Effects of exercise on side effects from gastrointestinal cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to determine the practical and safe levels of aerobic exercise that can positively impact patients undergoing treatment for gastrointestinal cancers. It will assess how structured treadmill walking influences the side effects of therapy and the body's response to exercise. The research will also evaluate treatment adherence, including the highest doses received and the need for additional medications to manage side effects. Participants will be closely monitored to ensure compliance with study procedures and exercise safety.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged ≥18 years
* Diagnosed with colorectal or esophago/gastric solid tumors as defined by one of the following:

  * Histological confirmation
  * As per standard of care imaging
* Scheduled to receive neoadjuvant chemotherapy or chemotherapy for newly diagnosed metastatic disease
* Performing ≤90 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluated by self-report
* Willingness to comply with all study-related procedures
* Cleared for exercise participation as per screening clearance via the Physical Activity Readiness Questionnaire

Exclusion Criteria:

* Enrollment onto any other lifestyle interventional investigational study, except interventions determined by the PI not to confound study outcomes
* Receiving treatment for any other diagnosis of invasive cancer
* Mental impairment leading to inability to cooperate
* Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation

Where it's running

• Hartford Healthcare Alliance (Data Collection Only)
  Hartford, Connecticut, United States Recruiting
• Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
  Basking Ridge, New Jersey, United States Recruiting
• Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
  Middletown, New Jersey, United States Recruiting
• Memorial Sloan Kettering Bergen (Limited Protocol Activities)
  Montvale, New Jersey, United States Recruiting
• Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
  Commack, New York, United States Recruiting
• Memorial Sloan Kettering Westchester (Limited Protocol Activities)
  Harrison, New York, United States Recruiting

Study contacts

• Principal investigator: Jessica Scott, PhD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Jessica Scott, PhD
• Email: scottj1@mskcc.org
• Phone: 646-888-8103

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Frailty before GI cancer surgery: does frailty predict post-op outcomes in older adults?

  This study tests whether frailty measured before surgery can predict complications and recovery in patients 60 and older undergoing elective gastrointestinal cancer surgery.

  Recruiting Van Training and Research Hospital · Van, Van · NCT07815392

• Biological Collection to Help Create Models for Digestive Cancers and IBD

  Researchers are gathering tissue and biological samples from patients with inflammatory bowel disease or digestive cancers to build personalized models and test new therapies.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07782203

• Blood extracellular vesicles to detect chemotherapy-related nerve damage.

  We will test whether tiny blood particles called extracellular vesicles can predict who will develop chemotherapy-induced peripheral neuropathy in adults receiving taxane, platinum, or antimitotic chemotherapy.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07558447

• High-precision detection of leftover cancer using a liquid-biopsy platform (SHERLOCK)

  This project will test whether sensitive blood and other fluid tests for circulating tumor DNA can find leftover cancer (minimal residual disease) in adults treated with curative intent for breast, lung, melanoma, gynecologic, or genitourinary cancers.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07524114

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

• XH001 with neoantigen vaccine–primed tumor-specific T cells for advanced gastrointestinal cancer

  This trial tests whether combining XH001 injections with T cells activated by a tumor neoantigen vaccine is safe and can shrink tumors or extend life in adults with advanced gastrointestinal cancer.

  Recruiting Phase 1 Beijing GoBroad Hospital · Beijing · NCT07329894

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.